Clinical bottom line
Long-acting injectable (LAI) antipsychotics are a valuable option for improving adherence in patients with schizophrenia and other psychotic disorders. They offer the potential to enhance treatment outcomes by ensuring consistent medication delivery, reducing relapse rates, and minimizing hospitalization. The choice of LAI should be individualized, considering patient preferences, previous treatment response, and side effect profiles.
What the evidence shows
LAI antipsychotics have been shown to improve adherence and reduce relapse rates compared to oral antipsychotics. A meta-analysis by Kishimoto et al. (2021) found that LAIs significantly reduced the risk of relapse in patients with schizophrenia, with a number needed to treat (NNT) of approximately 10 to prevent one relapse over a year (PMID: 33507242). This effect was more pronounced in patients with a history of poor adherence.
A systematic review by Kane et al. (2019) highlighted that LAIs are associated with fewer hospitalizations and longer time to relapse compared to oral formulations (PMID: 31162105). The review also noted that patient satisfaction with LAIs is generally high, particularly when patients are involved in the decision-making process.
Recent guidelines, such as those from the American Psychiatric Association (2020), recommend considering LAIs for patients with a history of non-adherence, frequent relapses, or those who prefer less frequent dosing (PMID: 31985729). These guidelines emphasize the importance of shared decision-making and patient education in optimizing treatment outcomes.
Caveats and uncertainty
While LAI antipsychotics offer several advantages, there are caveats to consider. The initial cost of LAIs can be higher than oral medications, potentially limiting accessibility for some patients. Additionally, the requirement for healthcare visits for administration may pose logistical challenges, particularly in resource-limited settings.
The choice of LAI should be guided by individual patient factors, including previous treatment response and side effect profiles. Some patients may experience injection site reactions or prefer oral medications due to needle aversion. Furthermore, the long duration of action of LAIs means that any adverse effects may persist longer than with oral formulations.
How this may change practice
The evidence supporting LAI antipsychotics underscores their role in improving adherence and reducing relapse rates in patients with schizophrenia and other psychotic disorders. Clinicians should consider LAIs as a viable option for patients with a history of non-adherence or frequent relapses, particularly when patient preferences align with this treatment modality.
In practice, this may lead to more frequent use of LAIs in clinical settings, with a focus on shared decision-making and patient education to optimize adherence and outcomes. As new evidence emerges, clinicians should remain informed about updates to guidelines and integrate these into their practice to ensure effective management of psychotic disorders.